KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Twist Bioscience (TWST) Total Current Liabilities (2018 - 2025)

Twist Bioscience (TWST) has disclosed Total Current Liabilities for 8 consecutive years, with $80.4 million as the latest value for Q4 2025.

  • Quarterly Total Current Liabilities rose 15.5% to $80.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $80.4 million through Dec 2025, up 15.5% year-over-year, with the annual reading at $91.4 million for FY2025, 28.73% up from the prior year.
  • Total Current Liabilities for Q4 2025 was $80.4 million at Twist Bioscience, down from $91.4 million in the prior quarter.
  • The five-year high for Total Current Liabilities was $92.7 million in Q2 2022, with the low at $40.4 million in Q1 2021.
  • Average Total Current Liabilities over 5 years is $74.5 million, with a median of $73.5 million recorded in 2023.
  • The sharpest move saw Total Current Liabilities surged 115.71% in 2021, then fell 22.2% in 2023.
  • Over 5 years, Total Current Liabilities stood at $80.0 million in 2021, then increased by 4.75% to $83.8 million in 2022, then decreased by 22.2% to $65.2 million in 2023, then rose by 6.77% to $69.6 million in 2024, then grew by 15.5% to $80.4 million in 2025.
  • According to Business Quant data, Total Current Liabilities over the past three periods came in at $80.4 million, $91.4 million, and $87.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.